Kang Seok Kyung, Kim Dong Il, Lee Seungju, Jung Youn Joo, Seo Jung Yeol, Nam Su Bong, Pak Kyoungjune, Lee Seokwon, Kim Hyun Yul
Department of Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Department of Surgery, Changwon Hanmaeum Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.
Transl Cancer Res. 2023 Oct 31;12(10):2717-2725. doi: 10.21037/tcr-23-706. Epub 2023 Oct 24.
We conducted a comprehensive systematic review of the literature and meta-analysis of the oncologic outcomes of breast reconstruction (BR) after mastectomy and mastectomy only. This study aimed to analyze the impact of BR on the prognosis of patients with breast cancer.
A systematic search of MEDLINE and EMBASE databases was performed using the following keywords: breast cancer, mastectomy, and BR. Inclusion criteria were studies reporting the survival data of patients after mastectomy only and mastectomy with BR. Event-free survival (EFS), breast cancer-specific survival (BCSS), and overall survival (OS) were considered the indicators of oncological outcomes. As all the included studies were non-randomized trials, we used the Newcastle-Ottawa Scale (NOS) for risk of bias assessment. The effect of BR on survival was measured using the effect size of the hazard ratio (HR). Data from each study were analyzed using the Review Manager.
Fifteen studies with 20,948 cases of BR and 63,358 cases of mastectomy were included. The pooled HRs for EFS and BCSS were 1.07 [95% confidence interval (CI): 0.78-1.47, P=0.65] and 0.84 (95% CI: 0.64-1.11, P=0.22), respectively. The patients who underwent BR after mastectomy had similar EFS and BCSS scores. Furthermore, patients who received BR had better OS (HR =0.73; 95% CI: 0.61-0.88, P=0.001) than those who underwent mastectomy only.
The data showed that BR after mastectomy had similar EFS and BCSS and better OS than mastectomy alone. Our meta-analysis suggests that BR is a practicable and safe treatment option for patients with breast cancer.
我们对乳房切除术后及单纯乳房切除术的乳房重建(BR)的肿瘤学结局进行了全面的系统文献综述和荟萃分析。本研究旨在分析BR对乳腺癌患者预后的影响。
使用以下关键词对MEDLINE和EMBASE数据库进行系统检索:乳腺癌、乳房切除术和BR。纳入标准为报告单纯乳房切除术后及乳房切除术后行BR患者生存数据的研究。无事件生存期(EFS)、乳腺癌特异性生存期(BCSS)和总生存期(OS)被视为肿瘤学结局指标。由于所有纳入研究均为非随机试验,我们使用纽卡斯尔-渥太华量表(NOS)进行偏倚风险评估。使用风险比(HR)的效应量来衡量BR对生存的影响。使用Review Manager对每项研究的数据进行分析。
纳入了15项研究,共20948例BR病例和63358例乳房切除术病例。EFS和BCSS的合并HR分别为1.07 [95%置信区间(CI):0.78 - 1.47,P = 0.65]和0.84(95% CI:0.64 - 1.11,P = 0.22)。乳房切除术后接受BR的患者具有相似的EFS和BCSS评分。此外,接受BR的患者比仅接受乳房切除术的患者具有更好的OS(HR = 0.73;95% CI:0.61 - 0.88,P = 0.001)。
数据表明,乳房切除术后行BR与单纯乳房切除术相比,具有相似的EFS和BCSS,且OS更好。我们的荟萃分析表明,BR是乳腺癌患者一种可行且安全的治疗选择。